Christophe Beck
Analyst · BMO Capital Markets. Proceed to your question.
So, two things, John, and very different stories, obviously, so in that segment. Life Science has been in a good place for a long time. They were just lapping against very high numbers during the years prior as well. So, it was more of a year-on-year comp than anything else. And Life Science, as mentioned before, is back to our 18% growth, driving very good earnings as well as they did prior during that comp was an issue and back ultimately to their traditional trajectory. So, life science in a very good place, which you see fully in Q4, and you couldn't see fully in Q3. Second, Purolite, as mentioned many times, so we were capped in terms of how much we could produce until Q4, which limited the growth by definition because we couldn't produce the products that we could sell ultimately. That has created a bump, obviously, in Q4. It's not in our organic numbers by definition, since it's an acquisition, and it's the first year. It's going to change as of Q1. And then you have Healthcare, totally different story. I like the fact that they're turning slightly to positive growth. The fact that they have made some money, but I'm not getting overly excited with that. It's one quarter, and it's not a dramatic change in that business. On the other hand, I like a lot the efforts that are being made by that team to really drive it back to the performance that it should be from a growth and, most importantly, from a margin perspective. The program we've announced is part of it that will help, obviously, the cost structure. But at the same time, we know that we need to improve our offering. We need to make sure we focus on the programs that make most sense as well for our customers and for us. So, it's still a long road ahead, but we will get to the right place as I've committed to that.